Fusion constructs and methods of using thereof
AssigneeIntrexon Corporation
InventorsHelen Sabzevari, Simon Metenou, ChangHung Chen, Rutul R. Shah
Life of this patent
Estimating the term…
Abstract
Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-β trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
Claims34
A fusion protein comprising:
- an antibody or a fragment of said antibody or a variant of said antibody that binds to programmed cell death protein-1 (PD-1);
- and
- a Transforming growth factor beta (TGF-β) cytokine trap;
- wherein one or more polypeptides of the fusion protein are connected by a linker.
-5. (canceled)
-14. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-52. (canceled)
-56. (canceled)
A method of treating a subject with a cancer, the method comprising:
- administering a composition comprising a fusion protein comprising
- an antibody or a fragment or a variant of said antibody that binds to programmed cell death protein-1 (PD-1);
- and
- a transforming growth factor receptor (TGFβR) or a functional fragment thereof, an anti-TGF-β antibody or an antigen binding fragment thereof, a TGF-β1 inhibitory peptide or a variant thereof;
- wherein one or more polypeptides of the fusion protein are connected by a linker.
-104. (canceled)
-116. (canceled)
Dependencies are inferred from the claim text.